[{"edinetCode":"E00987","endDate":"2017\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":61.0,"averageTemporaryStaff":3.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2067900.0,"sharesOwendPercent":0.2165,"outstandingShares":null,"numberOfSubsidiary":2.0,"bps":142.68,"equityRatio":0.622,"cashAndCashEquivalents":1856218000.0,"assets":2190386000.0,"currentAssets":2134250000.0,"fixedAsset":56136000.0,"tangibleFixedAssets":20381000.0,"intangibleFixedAssets":405000.0,"investmentAndOtherAssets":35349000.0,"liabilities":812477000.0,"currentLiabilities":341966000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":153997000.0,"fixedLiabilities":470511000.0,"bonds":144000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":298122000.0,"netAsset":1377908000.0,"capitalStock":1364003000.0,"capital":3226487000.0,"capitalSurplus":2044512000.0,"accumulatedEarnings":-3906897000.0,"treasuryStock":-99000.0,"valuationAndConversionAdjustments":-1186000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":657516000.0,"costOfSales":222502000.0,"grossProfit":435013000.0,"sgaExpenses":1134074000.0,"salaryAndBenefit":123680000.0,"depreciationAndSGA":null,"RDExpenses":670861000.0,"operatingIncome":-699060000.0,"nonOperatingIncome":6587000.0,"nonOperatingExpenses":19023000.0,"interestExpense":6901000.0,"ordinaryProfit":-711496000.0,"extraordinaryGain":null,"extraordinaryLoss":21884000.0,"incomeBeforeTax":-733380000.0,"incomeTaxes":3883000.0,"netIncome":-737264000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-737264000.0,"comprehensiveIncome":-738967000.0,"eps":-78.53,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-561055000.0,"depreciationAndCashflowFromOperatingActivities":12114000.0,"cashFlowFromInvestingActivities":-38131000.0,"cashFlowFromFinancialActivities":295814000.0,"changesInCashAndCashEquivalents":-304967000.0,"列1":"asr","submitDate":"2018\/3\/29","stockCode":4572,"accountingYear":"第15期(自　平成29年１月１日　至　平成29年12月31日)","accountingYearStart":"2017\/1\/1","accountingYearEnd":"2017\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2018\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":62.0,"averageTemporaryStaff":2.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2324700.0,"sharesOwendPercent":0.2293,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":86.83,"equityRatio":0.497,"cashAndCashEquivalents":1355254000.0,"assets":1770090000.0,"currentAssets":1671589000.0,"fixedAsset":98501000.0,"tangibleFixedAssets":18729000.0,"intangibleFixedAssets":183000.0,"investmentAndOtherAssets":79587000.0,"liabilities":882636000.0,"currentLiabilities":400139000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":204814000.0,"fixedLiabilities":482497000.0,"bonds":116000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":337755000.0,"netAsset":887453000.0,"capitalStock":883563000.0,"capital":3591568000.0,"capitalSurplus":2409593000.0,"accumulatedEarnings":-5117482000.0,"treasuryStock":-117000.0,"valuationAndConversionAdjustments":-3326000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":754691000.0,"costOfSales":250699000.0,"grossProfit":503992000.0,"sgaExpenses":1648511000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1140841000.0,"operatingIncome":-1144519000.0,"nonOperatingIncome":1115000.0,"nonOperatingExpenses":15820000.0,"interestExpense":10628000.0,"ordinaryProfit":-1159223000.0,"extraordinaryGain":null,"extraordinaryLoss":47575000.0,"incomeBeforeTax":-1206799000.0,"incomeTaxes":3773000.0,"netIncome":-1210573000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1210573000.0,"comprehensiveIncome":-1212712000.0,"eps":-125.02,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1128026000.0,"depreciationAndCashflowFromOperatingActivities":12716000.0,"cashFlowFromInvestingActivities":-58314000.0,"cashFlowFromFinancialActivities":687522000.0,"changesInCashAndCashEquivalents":-500964000.0,"列1":"asr","submitDate":"2019\/3\/27","stockCode":4572,"accountingYear":"第16期(自　平成30年１月１日　至　平成30年12月31日)","accountingYearStart":"2018\/1\/1","accountingYearEnd":"2018\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2019\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.527,"cashAndCashEquivalents":null,"assets":1600967000.0,"currentAssets":1505095000.0,"fixedAsset":95871000.0,"tangibleFixedAssets":21178000.0,"intangibleFixedAssets":170000.0,"investmentAndOtherAssets":74522000.0,"liabilities":753633000.0,"currentLiabilities":327786000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":186148000.0,"fixedLiabilities":425847000.0,"bonds":102000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":295011000.0,"netAsset":847333000.0,"capitalStock":845760000.0,"capital":3691074000.0,"capitalSurplus":2509099000.0,"accumulatedEarnings":-5354296000.0,"treasuryStock":-117000.0,"valuationAndConversionAdjustments":-2764000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":169964000.0,"costOfSales":43917000.0,"grossProfit":126046000.0,"sgaExpenses":359166000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-233119000.0,"nonOperatingIncome":652000.0,"nonOperatingExpenses":3415000.0,"interestExpense":2074000.0,"ordinaryProfit":-235883000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-235883000.0,"incomeTaxes":931000.0,"netIncome":-236814000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-236814000.0,"comprehensiveIncome":-236252000.0,"eps":-23.16,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/5\/14","stockCode":4572,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2019\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":2359040.0,"sharesOwendPercent":0.2177,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.717,"cashAndCashEquivalents":1324819000.0,"assets":3901020000.0,"currentAssets":3785747000.0,"fixedAsset":115273000.0,"tangibleFixedAssets":21144000.0,"intangibleFixedAssets":157000.0,"investmentAndOtherAssets":93971000.0,"liabilities":1101328000.0,"currentLiabilities":709128000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":173054000.0,"fixedLiabilities":392200000.0,"bonds":102000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":252267000.0,"netAsset":2799692000.0,"capitalStock":2801137000.0,"capital":3952466000.0,"capitalSurplus":2770491000.0,"accumulatedEarnings":-3921668000.0,"treasuryStock":-152000.0,"valuationAndConversionAdjustments":-5707000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":2460795000.0,"costOfSales":90029000.0,"grossProfit":2370765000.0,"sgaExpenses":919358000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":504005000.0,"operatingIncome":1451407000.0,"nonOperatingIncome":2878000.0,"nonOperatingExpenses":7934000.0,"interestExpense":3901000.0,"ordinaryProfit":1446350000.0,"extraordinaryGain":null,"extraordinaryLoss":25149000.0,"incomeBeforeTax":1421201000.0,"incomeTaxes":225387000.0,"netIncome":1195813000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1195813000.0,"comprehensiveIncome":1193431000.0,"eps":113.86,"dilutedEps":112.54,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-545158000.0,"depreciationAndCashflowFromOperatingActivities":3727000.0,"cashFlowFromInvestingActivities":-26120000.0,"cashFlowFromFinancialActivities":542174000.0,"changesInCashAndCashEquivalents":-30435000.0,"列1":"q2r","submitDate":"2019\/8\/14","stockCode":4572,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2019\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.677,"cashAndCashEquivalents":null,"assets":5128317000.0,"currentAssets":5023512000.0,"fixedAsset":104804000.0,"tangibleFixedAssets":21649000.0,"intangibleFixedAssets":286000.0,"investmentAndOtherAssets":82868000.0,"liabilities":1640432000.0,"currentLiabilities":1104867000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":270972000.0,"fixedLiabilities":535564000.0,"bonds":88000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":409527000.0,"netAsset":3487884000.0,"capitalStock":3477675000.0,"capital":4332118000.0,"capitalSurplus":3150143000.0,"accumulatedEarnings":-4004433000.0,"treasuryStock":-152000.0,"valuationAndConversionAdjustments":-3739000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":2862260000.0,"costOfSales":150254000.0,"grossProfit":2712006000.0,"sgaExpenses":1354991000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":1357015000.0,"nonOperatingIncome":6978000.0,"nonOperatingExpenses":17864000.0,"interestExpense":5628000.0,"ordinaryProfit":1346129000.0,"extraordinaryGain":null,"extraordinaryLoss":25936000.0,"incomeBeforeTax":1320192000.0,"incomeTaxes":207143000.0,"netIncome":1113049000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1113049000.0,"comprehensiveIncome":1112635000.0,"eps":104.16,"dilutedEps":102.07,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/11\/11","stockCode":4572,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2019\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":63.0,"averageTemporaryStaff":4.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3413892.0,"sharesOwendPercent":0.293,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":329.86,"equityRatio":0.715,"cashAndCashEquivalents":4915056000.0,"assets":5376610000.0,"currentAssets":5274893000.0,"fixedAsset":101717000.0,"tangibleFixedAssets":29799000.0,"intangibleFixedAssets":234000.0,"investmentAndOtherAssets":71683000.0,"liabilities":1523088000.0,"currentLiabilities":1055162000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":270972000.0,"fixedLiabilities":467926000.0,"bonds":88000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":341784000.0,"netAsset":3853522000.0,"capitalStock":3843543000.0,"capital":4657466000.0,"capitalSurplus":3475491000.0,"accumulatedEarnings":-4289192000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":-851000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":3207423000.0,"costOfSales":207590000.0,"grossProfit":2999833000.0,"sgaExpenses":2022055000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1281980000.0,"operatingIncome":977778000.0,"nonOperatingIncome":3282000.0,"nonOperatingExpenses":23900000.0,"interestExpense":8164000.0,"ordinaryProfit":957161000.0,"extraordinaryGain":null,"extraordinaryLoss":44101000.0,"incomeBeforeTax":913059000.0,"incomeTaxes":84770000.0,"netIncome":828289000.0,"netIncomeAttributableToOwnersOfTheParentCompany":828289000.0,"comprehensiveIncome":830764000.0,"eps":76.05,"dilutedEps":74.51,"dividendPerShare":null,"per":27.9,"roe":0.351,"cashFlowFromOperatingActivities":1477773000.0,"depreciationAndCashflowFromOperatingActivities":9394000.0,"cashFlowFromInvestingActivities":-40945000.0,"cashFlowFromFinancialActivities":2121748000.0,"changesInCashAndCashEquivalents":3559801000.0,"列1":"asr","submitDate":"2020\/3\/27","stockCode":4572,"accountingYear":"第17期(自　2019年１月１日　至　2019年12月31日)","accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2020\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.809,"cashAndCashEquivalents":null,"assets":5644519000.0,"currentAssets":5548572000.0,"fixedAsset":95947000.0,"tangibleFixedAssets":31324000.0,"intangibleFixedAssets":4270000.0,"investmentAndOtherAssets":60353000.0,"liabilities":1073860000.0,"currentLiabilities":669520000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":252925000.0,"fixedLiabilities":404340000.0,"bonds":74000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":292088000.0,"netAsset":4570659000.0,"capitalStock":4566865000.0,"capital":5111327000.0,"capitalSurplus":3929352000.0,"accumulatedEarnings":-4473591000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":-2338000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":335043000.0,"costOfSales":38451000.0,"grossProfit":296591000.0,"sgaExpenses":461667000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-165076000.0,"nonOperatingIncome":2393000.0,"nonOperatingExpenses":5936000.0,"interestExpense":2234000.0,"ordinaryProfit":-168619000.0,"extraordinaryGain":null,"extraordinaryLoss":15107000.0,"incomeBeforeTax":-183727000.0,"incomeTaxes":671000.0,"netIncome":-184399000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-184399000.0,"comprehensiveIncome":-185886000.0,"eps":-15.25,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/5\/13","stockCode":4572,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2020\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3144639.0,"sharesOwendPercent":0.2535,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.849,"cashAndCashEquivalents":4920579000.0,"assets":5349010000.0,"currentAssets":5222300000.0,"fixedAsset":126710000.0,"tangibleFixedAssets":29172000.0,"intangibleFixedAssets":4051000.0,"investmentAndOtherAssets":93486000.0,"liabilities":805571000.0,"currentLiabilities":439695000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":223759000.0,"fixedLiabilities":365876000.0,"bonds":74000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":253511000.0,"netAsset":4543439000.0,"capitalStock":4543686000.0,"capital":558829000.0,"capitalSurplus":4310038000.0,"accumulatedEarnings":-324958000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":-3798000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":579703000.0,"costOfSales":80645000.0,"grossProfit":499057000.0,"sgaExpenses":874328000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":615596000.0,"operatingIncome":-375271000.0,"nonOperatingIncome":3627000.0,"nonOperatingExpenses":9331000.0,"interestExpense":4204000.0,"ordinaryProfit":-380975000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":16371000.0,"incomeBeforeTax":-396346000.0,"incomeTaxes":1168000.0,"netIncome":-397514000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-397514000.0,"comprehensiveIncome":-400461000.0,"eps":-32.6,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-822976000.0,"depreciationAndCashflowFromOperatingActivities":5694000.0,"cashFlowFromInvestingActivities":-42864000.0,"cashFlowFromFinancialActivities":873923000.0,"changesInCashAndCashEquivalents":5523000.0,"列1":"q2r","submitDate":"2020\/8\/11","stockCode":4572,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2020\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.82,"cashAndCashEquivalents":null,"assets":5227840000.0,"currentAssets":5113435000.0,"fixedAsset":114404000.0,"tangibleFixedAssets":27059000.0,"intangibleFixedAssets":3832000.0,"investmentAndOtherAssets":83512000.0,"liabilities":938028000.0,"currentLiabilities":624647000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":194633000.0,"fixedLiabilities":313381000.0,"bonds":60000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":214894000.0,"netAsset":4289811000.0,"capitalStock":4292063000.0,"capital":558829000.0,"capitalSurplus":4310038000.0,"accumulatedEarnings":-576582000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":-5802000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":847647000.0,"costOfSales":132750000.0,"grossProfit":714897000.0,"sgaExpenses":1330581000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-615684000.0,"nonOperatingIncome":1518000.0,"nonOperatingExpenses":11437000.0,"interestExpense":5921000.0,"ordinaryProfit":-625604000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":22782000.0,"incomeBeforeTax":-647386000.0,"incomeTaxes":1751000.0,"netIncome":-649138000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-649138000.0,"comprehensiveIncome":-654089000.0,"eps":-52.93,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/11\/10","stockCode":4572,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":64.0,"averageTemporaryStaff":4.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3168389.0,"sharesOwendPercent":0.2554,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":308.05,"equityRatio":0.79,"cashAndCashEquivalents":4299142000.0,"assets":4835356000.0,"currentAssets":4708193000.0,"fixedAsset":127162000.0,"tangibleFixedAssets":53330000.0,"intangibleFixedAssets":3613000.0,"investmentAndOtherAssets":70218000.0,"liabilities":1011346000.0,"currentLiabilities":727194000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":161897000.0,"fixedLiabilities":284151000.0,"bonds":60000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":179887000.0,"netAsset":3824010000.0,"capitalStock":3830169000.0,"capital":558829000.0,"capitalSurplus":4310038000.0,"accumulatedEarnings":-1038476000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":-9709000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":1133346000.0,"costOfSales":192149000.0,"grossProfit":941196000.0,"sgaExpenses":1998264000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1474452000.0,"operatingIncome":-1057067000.0,"nonOperatingIncome":2749000.0,"nonOperatingExpenses":22778000.0,"interestExpense":7373000.0,"ordinaryProfit":-1077096000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":26390000.0,"incomeBeforeTax":-1102487000.0,"incomeTaxes":8545000.0,"netIncome":-1111032000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1111032000.0,"comprehensiveIncome":-1119890000.0,"eps":-90.33,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1260972000.0,"depreciationAndCashflowFromOperatingActivities":12410000.0,"cashFlowFromInvestingActivities":-70433000.0,"cashFlowFromFinancialActivities":724423000.0,"changesInCashAndCashEquivalents":-615914000.0,"列1":"asr","submitDate":"2021\/3\/26","stockCode":4572,"accountingYear":"第18期(自　2020年１月１日　至　2020年12月31日)","accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.839,"cashAndCashEquivalents":null,"assets":4228189000.0,"currentAssets":4108725000.0,"fixedAsset":119463000.0,"tangibleFixedAssets":54105000.0,"intangibleFixedAssets":3394000.0,"investmentAndOtherAssets":61963000.0,"liabilities":677808000.0,"currentLiabilities":442025000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":147208000.0,"fixedLiabilities":235783000.0,"bonds":46000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":144880000.0,"netAsset":3550380000.0,"capitalStock":3543837000.0,"capital":558829000.0,"capitalSurplus":4310038000.0,"accumulatedEarnings":-1324807000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":2991000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":231278000.0,"costOfSales":38677000.0,"grossProfit":192601000.0,"sgaExpenses":483814000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-291213000.0,"nonOperatingIncome":8690000.0,"nonOperatingExpenses":1532000.0,"interestExpense":1169000.0,"ordinaryProfit":-284055000.0,"extraordinaryGain":null,"extraordinaryLoss":1755000.0,"incomeBeforeTax":-285810000.0,"incomeTaxes":520000.0,"netIncome":-286331000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-286331000.0,"comprehensiveIncome":-273630000.0,"eps":-23.09,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/5\/11","stockCode":4572,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3334215.0,"sharesOwendPercent":0.2682,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.845,"cashAndCashEquivalents":3213070000.0,"assets":3662494000.0,"currentAssets":3522280000.0,"fixedAsset":140213000.0,"tangibleFixedAssets":58373000.0,"intangibleFixedAssets":3210000.0,"investmentAndOtherAssets":78629000.0,"liabilities":565770000.0,"currentLiabilities":370736000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":143638000.0,"fixedLiabilities":195033000.0,"bonds":46000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":109873000.0,"netAsset":3096723000.0,"capitalStock":3091989000.0,"capital":577975000.0,"capitalSurplus":4329185000.0,"accumulatedEarnings":-1814948000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":1183000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":430010000.0,"costOfSales":69043000.0,"grossProfit":360967000.0,"sgaExpenses":1138307000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":877898000.0,"operatingIncome":-777339000.0,"nonOperatingIncome":8245000.0,"nonOperatingExpenses":5637000.0,"interestExpense":2194000.0,"ordinaryProfit":-774731000.0,"extraordinaryGain":null,"extraordinaryLoss":6108000.0,"incomeBeforeTax":-780840000.0,"incomeTaxes":-4367000.0,"netIncome":-776472000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-776472000.0,"comprehensiveIncome":-765579000.0,"eps":-62.56,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-963337000.0,"depreciationAndCashflowFromOperatingActivities":9079000.0,"cashFlowFromInvestingActivities":-34339000.0,"cashFlowFromFinancialActivities":-102287000.0,"changesInCashAndCashEquivalents":-1086072000.0,"列1":"q2r","submitDate":"2021\/8\/10","stockCode":4572,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.824,"cashAndCashEquivalents":null,"assets":4211341000.0,"currentAssets":4084001000.0,"fixedAsset":127339000.0,"tangibleFixedAssets":54556000.0,"intangibleFixedAssets":2974000.0,"investmentAndOtherAssets":69808000.0,"liabilities":731616000.0,"currentLiabilities":584313000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":140040000.0,"fixedLiabilities":147302000.0,"bonds":32000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":74854000.0,"netAsset":3479725000.0,"capitalStock":3462667000.0,"capital":964115000.0,"capitalSurplus":4715325000.0,"accumulatedEarnings":-2216551000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":6099000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":636512000.0,"costOfSales":95794000.0,"grossProfit":540717000.0,"sgaExpenses":1709734000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1169016000.0,"nonOperatingIncome":10345000.0,"nonOperatingExpenses":13143000.0,"interestExpense":3081000.0,"ordinaryProfit":-1171814000.0,"extraordinaryGain":null,"extraordinaryLoss":6108000.0,"incomeBeforeTax":-1177923000.0,"incomeTaxes":151000.0,"netIncome":-1178075000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1178075000.0,"comprehensiveIncome":-1162265000.0,"eps":-94.24,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/11\/9","stockCode":4572,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0},{"edinetCode":"E00987","endDate":"2021\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":64.0,"averageTemporaryStaff":9.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":3744477.0,"sharesOwendPercent":0.2813,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":323.54,"equityRatio":0.793,"cashAndCashEquivalents":3817834000.0,"assets":5432560000.0,"currentAssets":5318487000.0,"fixedAsset":114073000.0,"tangibleFixedAssets":51574000.0,"intangibleFixedAssets":2738000.0,"investmentAndOtherAssets":59760000.0,"liabilities":1116988000.0,"currentLiabilities":774655000.0,"shorTermDept":null,"currentPortionOfBonds":28000000.0,"currentPortionOfLongTermDebt":211497000.0,"fixedLiabilities":342332000.0,"bonds":32000000.0,"convertibleBond":null,"commercialPaper":null,"longTermDebts":268390000.0,"netAsset":4315572000.0,"capitalStock":4291942000.0,"capital":1056953000.0,"capitalSurplus":4808163000.0,"accumulatedEarnings":-1572951000.0,"treasuryStock":-222000.0,"valuationAndConversionAdjustments":13789000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":2017529000.0,"costOfSales":135387000.0,"grossProfit":1882141000.0,"sgaExpenses":2413277000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1841854000.0,"operatingIncome":-531135000.0,"nonOperatingIncome":24315000.0,"nonOperatingExpenses":16172000.0,"interestExpense":3925000.0,"ordinaryProfit":-522992000.0,"extraordinaryGain":null,"extraordinaryLoss":9507000.0,"incomeBeforeTax":-532499000.0,"incomeTaxes":1975000.0,"netIncome":-534474000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-534474000.0,"comprehensiveIncome":-510976000.0,"eps":-42.1,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1536612000.0,"depreciationAndCashflowFromOperatingActivities":19164000.0,"cashFlowFromInvestingActivities":-41677000.0,"cashFlowFromFinancialActivities":1064987000.0,"changesInCashAndCashEquivalents":-481307000.0,"列1":"asr","submitDate":"2022\/3\/25","stockCode":4572,"accountingYear":"第19期(自　2021年1月1日　至　2021年12月31日)","accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00987","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":5062,"settlementDate":null,"submitterName":"カルナバイオサイエンス株式会社","submitterNameEnglish":"Carna Biosciences, Inc.","submitterNameKana":"カルナバイオサイエンスカブシキガイシャ","location":"神戸市中央区港島南町一丁目５番５号","industory":"医薬品","corporateNumber":8140000000000.0}]